Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.

Amgen (NASDAQ:AMGN) reported second quarter earnings above expectations for the fourth time in a row, while also posting a ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

For the full year, Amgen narrowed its earnings outlook to between $19.20 and $20.00 per share, from $19.10 to $20.10. It also raised the midpoint of its revenue forecast and now expects $33 ...

Amgen narrowed its 2024 adjusted earnings estimate and now expects a profit of $19.10 to $20.10 per share, compared with its previous view of $19.00 to $20.20.

Amgen raised its full-year 2008 guidance to between $4.45 and $4.55 per share, compared to an earlier forecast of $4.25 to $4.45. Analysts have been expecting $4.38.

By Deena Beasley April 27 (Reuters) - Amgen Inc AMGN.O on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from ...

Amgen Inc <AMGN.O>, which is attempting to buy Onyx Pharmaceuticals Inc <ONXX.O> to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as ...

Amgen Inc., the world’s largest biotechnology company, said third-quarter net income fell 8.1%, though sales increased for its two biggest drugs, Epogen and Neupogen. Net income fell to $329.9 ...